Matinas BioPharma Holdings Inc (FRA:6LJ0)
€ 2.69 0 (0%) Market Cap: 15.88 Mil Enterprise Value: 5.92 Mil PE Ratio: 0 PB Ratio: 0.92 GF Score: 52/100

Q3 2022 Matinas BioPharma Holdings Inc Earnings Call Transcript

Nov 02, 2022 / 08:30PM GMT
Release Date Price: €39.77 (-0.70%)
Operator

Welcome to the Matinas BioPharma Third Quarter 2021 Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to Dr. Ankit Bhargava, Investor Relations Representative for Matinas BioPharma. You may begin.

Ankit Bhargava;Allele Capital Partners;Managing Director

Thank you, Dagma. Good afternoon, everyone, and thank you for joining the Matinas BioPharma Third Quarter 2022 Results Conference Call. Earlier this afternoon, we issued a press release with our financial results along with business updates. The release is available on the Matinas BioPharma website under the Investors section. These are -- there are slides accompanying today's presentation, which are available by joining the webcast through the Investors section of the company website. Speaking on today's call will be Jerry Jabbour, Chief Executive Officer; Dr. Terry Matkovits, Chief Development Officer; Dr. Terry Ferguson, Chief Medical Officer; and Keith Kucinski, Chief Financial Officer. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot